NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $165 | $582 | $1,423 | $2,247 |
| % Growth | -71.6% | -59.1% | -36.7% | – |
| Cost of Goods Sold | $518 | $500 | $1,119 | $1,119 |
| Gross Profit | -$353 | $82 | $304 | $1,128 |
| % Margin | -213.9% | 14.1% | 21.4% | 50.2% |
| R&D Expenses | $21,372 | $22,942 | $32,351 | $40,857 |
| G&A Expenses | $7,938 | $8,671 | $9,647 | $11,584 |
| SG&A Expenses | $7,938 | $8,671 | $9,647 | $11,584 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$48 | -$15 | -$134 | -$37 |
| Operating Expenses | $29,310 | $31,613 | $41,998 | $52,441 |
| Operating Income | -$29,663 | -$31,031 | -$40,575 | -$50,194 |
| % Margin | -17,977.6% | -5,331.8% | -2,851.4% | -2,233.8% |
| Other Income/Exp. Net | $1,993 | $2,234 | $2,314 | $2,547 |
| Pre-Tax Income | -$27,670 | -$28,797 | -$38,261 | -$47,647 |
| Tax Expense | $0 | $0 | $0 | -$2,547 |
| Net Income | -$27,670 | -$28,797 | -$38,261 | -$45,100 |
| % Margin | -16,769.7% | -4,947.9% | -2,688.8% | -2,007.1% |
| EPS | -0.33 | -0.35 | -0.46 | -0.55 |
| % Growth | 5.7% | 23.9% | 16.4% | – |
| EPS Diluted | -0.33 | -0.35 | -0.46 | -0.55 |
| Weighted Avg Shares Out | 82,803 | 82,707 | 82,456 | 82,008 |
| Weighted Avg Shares Out Dil | 82,803 | 82,707 | 82,456 | 82,008 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,041 | $2,249 | $2,448 | $2,584 |
| Interest Expense | $2,547 | $0 | $0 | $0 |
| Depreciation & Amortization | $518 | $535 | $559 | $609 |
| EBITDA | -$24,605 | -$30,496 | -$40,016 | -$50,194 |
| % Margin | -14,912.1% | -5,239.9% | -2,812.1% | -2,233.8% |